Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

580
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
580
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.1K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.1K
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

10.9K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
10.9K
Group Design02:01

Group Design

10.3K
The most basic experimental design involves two groups: the experimental group and the control group. The two groups are designed to be the same except for one difference— experimental manipulation. The experimental group gets the experimental manipulation—that is, the treatment or variable being tested—and the control group does not. Since experimental manipulation is the only difference between the experimental and control groups, we can be sure that any differences between...
10.3K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

469
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
469
Dehydration Synthesis01:15

Dehydration Synthesis

149.0K
Overview
Dehydration synthesis (also called a condensation reaction) is the chemical process in which two molecules covalently link together to form a new molecule, along with the release of a water molecule. Many physiologically important compounds form by dehydration synthesis reactions, such as complex carbohydrates, proteins, DNA, and RNA.
Synthesis of carbohydrates
Sugar molecules are covalently linked together by dehydration synthesis. During the reaction, the hydroxyl (-OH) group from...
149.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Plant-Induced Transcriptional Plasticity Diverges Between Generalist and Specialist Herbivores.

Molecular ecology·2026
Same author

Nutritional specialization and social evolution in woodroaches and termites.

Science (New York, N.Y.)·2026
Same author

Discovery of an orally bioavailable pyridone-based BRD4 inhibitor with potent antitumor efficacy in colorectal cancer.

European journal of medicinal chemistry·2026
Same author

The genetics and evolution of moth melanism in the absence of strong natural selection.

National science review·2026
Same author

Coordinated horizontal transfer of multiple genes assembles a carotenoid biosynthesis pathway in aphids.

Insect biochemistry and molecular biology·2025
Same author

KHSRP protects colorectal cancer cells against ferroptosis by regulating GPX4 expression through interaction with hnRNPM.

Experimental cell research·2025

Related Experiment Video

Updated: Jan 24, 2026

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment
06:47

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment

Published on: September 27, 2017

10.1K

Design, Synthesis, and Evaluation of a Potent and Selective ROCK2 Inhibitor for Atopic Dermatitis Treatment.

Churu Mao1, Shuai Zhan1, Zhangyun Fang1

  • 1Institute of Marine Biology and Pharmacology, Ocean College, Zhejiang University, Zhoushan 316021, China.

Journal of Medicinal Chemistry
|January 23, 2026
PubMed
Summary

A new drug, 10d, targets ROCK2 to treat atopic dermatitis (AD). This selective inhibitor shows superior efficacy and safety in preclinical models by downregulating S100A9, offering a novel therapeutic approach for AD.

More Related Videos

Synthesis and Evaluation of a Ruthenium-based Mitochondrial Calcium Uptake Inhibitor
07:12

Synthesis and Evaluation of a Ruthenium-based Mitochondrial Calcium Uptake Inhibitor

Published on: October 26, 2017

8.2K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.6K

Related Experiment Videos

Last Updated: Jan 24, 2026

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment
06:47

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment

Published on: September 27, 2017

10.1K
Synthesis and Evaluation of a Ruthenium-based Mitochondrial Calcium Uptake Inhibitor
07:12

Synthesis and Evaluation of a Ruthenium-based Mitochondrial Calcium Uptake Inhibitor

Published on: October 26, 2017

8.2K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.6K

Area of Science:

  • Pharmacology
  • Immunology
  • Structural Biology

Background:

  • Atopic dermatitis (AD) presents significant therapeutic challenges due to limited efficacy and safety of existing treatments.
  • Current therapies for AD often fail to address the underlying disease mechanisms effectively.
  • There is a critical need for novel therapeutic strategies targeting specific molecular pathways in AD.

Purpose of the Study:

  • To identify and develop a novel, potent, and selective inhibitor of ROCK2 for the treatment of atopic dermatitis.
  • To explore the therapeutic potential of targeting the ROCK2-S100A9 axis in AD.
  • To evaluate the efficacy and safety of a newly discovered ROCK2 inhibitor, compound 10d, in a preclinical model of AD.

Main Methods:

  • Structure-guided analysis of ROCK2 to identify unique structural features for drug design.
  • Virtual screening to discover small molecules targeting the identified hydrophobic surface (S1) of ROCK2.
  • In vitro characterization of compound 10d for ROCK2 inhibition potency and selectivity against reference compound KD025.
  • Assessment of compound 10d efficacy and safety in a MC903-induced mouse model of atopic dermatitis.
  • Mechanistic studies to elucidate the downstream effects of ROCK2 inhibition by 10d, focusing on S100A9.

Main Results:

  • Identification of a unique hydrophobic surface (S1) on ROCK2, enabling structure-based drug design.
  • Discovery of compound 10d, a highly potent and selective ROCK2 inhibitor with improved properties over KD025.
  • Demonstration of significant therapeutic efficacy of 10d in suppressing inflammation and improving AD pathology in a mouse model.
  • Favorable safety profile observed for compound 10d in the preclinical AD model.
  • Confirmation that 10d attenuates AD pathology by downregulating S100A9, validating the ROCK2-S100A9 pathway.

Conclusions:

  • Compound 10d is a highly active and selective ROCK2 inhibitor with significant therapeutic potential for atopic dermatitis.
  • The ROCK2-S100A9 axis represents a novel and promising therapeutic target for AD.
  • This study provides the first evidence for ROCK2-targeted therapy in AD, establishing 10d as a lead candidate for further development.